FindTrial
Sign In

Effcets of 5-HTR2A, DRD2,and COMT genes polymorphisms and drug plasma concentration on antipsychotic response to olanzapine in treatment of early-onset schizophrenia

Effcets of 5-HTR2A, DRD2,and COMT genes polymorphisms and drug plasma concentration on antipsychotic response to olanzapine in treatment of early-onset schizophrenia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-15006331
Enrollment
Unknown
Registered
2015-04-21
Start date
2015-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early-onset schizophrenia

Interventions

Case series:Nil

Sponsors

First Affiliated Hospital Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 17 Years

Inclusion criteria

Inclusion criteria: 1. above 7 years old, age of onset =70 points; 2. patients are in the condition of first-episode, or relapse, but is currently in the discontinuation of antipsychotic treatment for 3 months or more.

Exclusion criteria

Exclusion criteria: IQ <75, current or previous history of traumatic brain injury, psychoactive substance use, personality disorders, obvious abnormalities on physical and laboratory examination, previous allergy or olanzapine had significant adverse reactions.

Design outcomes

Primary

MeasureTime frame
olanzapine plasma concentration;Positive and Negative Syndrome Scale;Children's Global Assessment Scale;Wisconsin Card Sorting Test;continue performance test;stroop test;Event-related Potentials;polymorphisms loci test of 5-HTR2A, DRD2 and COMT genes;—

Secondary

MeasureTime frame
laboratory test;—

Contacts

Public ContactKang Chuanyuan
kangbao98@163.com+86 15925193980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026